Phaseline

Companies › Shanghai BDgene

Shanghai BDgene: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Hematology, Infectious disease; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BD111
CRISPR/Cas9-based lentiviral particles targeting HSV-1 genes
HSV1Phase 2Herpes Simplex Virus Type I Stromal KeratitisDec 2026
BD211
Lentiviral vector-transduced autologous CD34+ hematopoietic stem cells expressing βA-T87Q-
–Phase 1β-thalassemiaDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06474416BD111Phase 1Herpes Simplex Virus Type I Stromal KeratitisInfectious diseaseOct 2025
NCT06465550BD211Phase 1β-thalassemiaHematologyDec 2026
NCT06474442BD111Phase 2Herpes Simplex Virus Type I Stromal KeratitisInfectious diseaseDec 2026

Targets

HSV1 (1)

Companies with the same targets

–

Companies built like this

InventVacc Biologicals Serum Institute of India CanSino Biologics Aimei Vacin BioPharm (Zhejiang) Shanghai Xinzhi BioMed

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.